Top-News
Donnerstag,
21.11.2019 17:00
von
GlobeNewswire
| Aufrufe: 1084
ContextVision announces first digital pathology patent granted for its unique and objective data-generation method
Server in einem Rechenzentrum. (Symbolfoto)
© gopixa / iStock / Getty Images Plus / Getty Images
http://www.gettyimages.de
STOCKHOLM – November 21, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, announce today that its proprietary Master Annotation method has received patent protection in the U.S.
The U.S. Patent and Trademark Office (USPTO) has granted a patent to ContextVision for this invention, titled “method and system for detecting pathological anomalies in a digital pathology image and method for annotating a tissue slide”.
ContextVision developed this method to automatically and more objectively outline specific structures in pathology images used for training deep learning algorithms. It identifies and highlights cancer areas and other structures by using multi-plex immunofluorescent staining. This enables development of algorithms based on objective data with high accuracy.
“This patent protection is a milestone for ContextVision, and I´m so happy and proud to see this idea become reality. Thanks to a strong team effort we have managed to implement the invention as a standard component in our product development,” said Kristian Eurén at ContextVision, inventor of the Master Annotation method and product manager.
The upcoming product, INIFY Prostate Screening, learns by using the patented Master Annotation method. INIFY Prostate Screening is a powerful AI-based software that outlines and quantifies suspected cancerous areas in a series of prostate biopsies. It pre-sorts slides in a worst-first order, allowing pathologists to get right to work on the most relevant areas. The product is currently in beta-test phase.
“This is a clear proof of the innovative capacity we have in our multidisciplinary team. We are dedicated to developing best-in-class decision support tools for highly accurate diagnosis and prognostication of cancer. The accuracy of the algorithms we develop depends strongly on what we feed into our neural networks,” said Fredrik Palm, ContextVision CEO. “Strengthened by this achievement, we continue with confidence towards the growing digital pathology market”.
For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43 or visit www.contextvision.com.
###
About ContextVision
ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence. As the global market leader within image enhancement, ContextVision is a software partner to leading medical imaging manufacturers around the world. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
As an industry pioneer for more than 30 years, ContextVision has developed state-of-the-art capabilities in the latest artificial intelligence technologies. By combining these with its well-established GOP technology, the company is introducing a new generation of image enhancement products. ContextVision are determined to expand by approaching the growing digital pathology market with new AI-based decision support tools for pathologists.
The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.
###
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
This information is information that ContextVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on November 21, 2019.
Attachment
Werbung
Mehr Nachrichten zur CONTEXTVISION SK 0,25 Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
